A new start­up sets course against a con­stel­la­tion of rare dis­eases with a first shot re­pur­pos­ing the SIRP path­way

De­spite some big ad­vances in re­cent years, rare dis­ease re­mains a most­ly un­chart­ed wilder­ness with many pa­tients left un­der­served. A start­up with galac­tic am­bi­tions now hopes to bust open a wide range of such dis­eases, and its first ef­fort has eyes on a fa­mil­iar can­cer tar­get.

Star Ther­a­peu­tics emerged from stealth Wednes­day fo­cused on crack­ing the code in a con­stel­la­tion of rare dis­eases with a first spin­out com­pa­ny tar­get­ing the SIRP path­way for im­munol­o­gy and can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER